Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1990; 16:1408-1414
© 1990 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boahene, K.
Right arrow Articles by Fujimura, O
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boahene, K.
Right arrow Articles by Fujimura, O

Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length

KA Boahene, GJ Klein, R Yee, AD Sharma, and O Fujimura

Department of Medicine, University Hospital, London, Ontario, Canada.

The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome. All patients received either procainamide (12 to 15 mg/kg body weight) or propafenone (1 to 2 mg/kg) during sustained (greater than 10 min) atrial fibrillation or after termination of nonsustained atrial fibrillation. Termination of atrial fibrillation was attributed to a drug if it occurred less than or equal to 15 min after infusion. Measurements included mean cycle length of fibrillatory electrograms (mean AA interval) as measured at the high right atrium and shortest RR interval between pre-excited cycles during atrial fibrillation. Atrial fibrillation terminated more frequently after procainamide administration (65%) than after propafenone (46%), although this difference was not significant. Procainamide prolonged the shortest pre-excited RR interval (228 +/- 41 to 339 +/- 23 ms, p = 0.0001) as did propafenone (215 +/- 40 to 415 +/- 198 ms, p = 0.0001) and the magnitude of increase was greater for propafenone (p = 0.048). Patients with sustained atrial fibrillation had shorter mean AA intervals than did their counterparts with nonsustained atrial fibrillation (123 +/- 25 versus 186 +/- 35 ms, p = 0.0001). Termination of sustained atrial fibrillation by either drug was accompanied by prolongation of the mean AA interval but not necessarily by the shortest pre-excited RR interval. Termination of atrial fibrillation was heralded by a 68% increase in the mean AA interval after procainamide administration compared with a 30% increase when the arrhythmia persisted. For propafenone the increases were 90% and 68%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
EuropaceHome page
A. Bollmann, D. Husser, L. Mainardi, F. Lombardi, P. Langley, A. Murray, J. J. Rieta, J. Millet, S. B. Olsson, M. Stridh, et al.
Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications.
Europace, November 1, 2006; 8(11): 911 - 926.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
null The International Liaison Committee on Resuscitati
The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support
Pediatrics, May 1, 2006; 117(5): e955 - e977.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Part 6: Pediatric Basic and Advanced Life Support
Circulation, November 29, 2005; 112(22_suppl): III-73 - III-90.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Roy, B. H. Rowe, I. G. Stiell, B. Coutu, J. H. Ip, D. Phaneuf, J. Lee, H. Vidaillet, G. Dickinson, S. Grant, et al.
A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation
J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2355 - 2361.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Bollmann
Quantification of electrical remodeling in human atrial fibrillation
Cardiovasc Res, August 1, 2000; 47(2): 207 - 209.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Bollmann, K. Sonne, H.-D. Esperer, I. Toepffer, J. J Langberg, and H. U Klein
Non-invasive assessment of fibrillatory activity in patients with paroxysmal and persistent atrial fibrillation using the Holter ECG
Cardiovasc Res, October 1, 1999; 44(1): 60 - 66.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. S. Stambler, M. A. Wood, and K. A. Ellenbogen
Antiarrhythmic Actions of Intravenous Ibutilide Compared With Procainamide During Human Atrial Flutter and Fibrillation : Electrophysiological Determinants of Enhanced Conversion Efficacy
Circulation, December 16, 1997; 96(12): 4298 - 4306.
[Abstract] [Full Text]


Home page
CirculationHome page
B. S. Stambler, M. A. Wood, K. A. Ellenbogen, K. T. Perry, L. K. Wakefield, and J. T. VanderLugt
Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation
Circulation, October 1, 1996; 94(7): 1613 - 1621.
[Abstract] [Full Text]


Home page
CirculationHome page
A. Capucci, M. Biffi, G. Boriani, F. Ravelli, G. Nollo, P. Sabbatani, C. Orsi, and B. Magnani
Dynamic Electrophysiological Behavior of Human Atria During Paroxysmal Atrial Fibrillation
Circulation, September 1, 1995; 92(5): 1193 - 1202.
[Abstract] [Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement